Bruce L. Levine
#133,424
Most Influential Person Now
Researcher
Bruce L. Levine's AcademicInfluence.com Rankings
Bruce L. Levineengineering Degrees
Engineering
#4687
World Rank
#5898
Historical Rank
Biomedical Engineering
#310
World Rank
#317
Historical Rank
Applied Physics
#1205
World Rank
#1233
Historical Rank
Bruce L. Levinebiology Degrees
Biology
#8957
World Rank
#12104
Historical Rank
Virology
#202
World Rank
#208
Historical Rank
Cell Biology
#371
World Rank
#381
Historical Rank
Immunology
#525
World Rank
#542
Historical Rank
Download Badge
Engineering Biology
Bruce L. Levine's Degrees
- PhD Biomedical Engineering University of California, Berkeley
- Masters Biomedical Engineering Stanford University
Why Is Bruce L. Levine Influential?
(Suggest an Edit or Addition)Bruce L. Levine's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Chimeric antigen receptor T cells for sustained remissions in leukemia. (2014) (4010)
- Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. (2011) (2993)
- Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia (2018) (2931)
- Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. (2013) (2847)
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia (2011) (2173)
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia (2015) (1326)
- Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. (2014) (1231)
- Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas (2017) (1126)
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma (2017) (1047)
- Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. (2011) (1002)
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. (2013) (896)
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia (2018) (880)
- Engineered T cells: the promise and challenges of cancer immunotherapy (2016) (803)
- Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. (2016) (730)
- NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma (2015) (696)
- CRISPR-engineered T cells in patients with refractory cancer (2020) (685)
- Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies (2013) (665)
- Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells (2012) (575)
- Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells (2013) (521)
- Gene transfer in humans using a conditionally replicating lentiviral vector (2006) (498)
- Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. (2015) (487)
- Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells (2018) (466)
- Human naive and memory T lymphocytes differ in telomeric length and replicative potential. (1995) (437)
- Global Manufacturing of CAR T Cell Therapy (2016) (425)
- Regulated expression of telomerase activity in human T lymphocyte development and activation (1996) (424)
- B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. (2019) (404)
- Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. (2010) (389)
- L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. (2004) (382)
- The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells (2011) (376)
- Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell (2018) (374)
- T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans (2013) (371)
- Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. (2016) (359)
- PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. (2017) (358)
- Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. (1997) (356)
- Massive ex Vivo Expansion of Human Natural Regulatory T Cells (Tregs) with Minimal Loss of in Vivo Functional Activity (2011) (347)
- Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. (2016) (312)
- In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. (2004) (310)
- Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. (2004) (307)
- Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer (2005) (306)
- Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. (2018) (266)
- Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. (2010) (264)
- Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. (2007) (263)
- Adoptive immunotherapy for cancer or viruses. (2014) (255)
- Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer (2018) (251)
- Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes. (1999) (244)
- Antiviral Effect and Ex Vivo CD4+ T Cell Proliferation in HIV-Positive Patients as a Result of CD28 Costimulation (1996) (233)
- Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. (1997) (227)
- Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. (2017) (226)
- Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer (2017) (225)
- A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. (2006) (221)
- Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. (2000) (214)
- Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging (1997) (204)
- Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection (2002) (184)
- Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. (2003) (183)
- CD28 Costimulation Is Essential for Human T Regulatory Expansion and Function1 (2008) (174)
- Identification and In Vitro Expansion of Functional Antigen-Specific CD25+ FoxP3+ Regulatory T Cells in Hepatitis C Virus Infection (2008) (166)
- A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside (2013) (165)
- Decade-long leukaemia remissions with persistence of CD4+ CAR T cells (2022) (164)
- Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. (2005) (161)
- Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. (2011) (156)
- Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. (2019) (154)
- CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro. (1995) (153)
- 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. (2010) (147)
- Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. (2009) (147)
- Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer (2013) (143)
- Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells (2018) (139)
- Cutting Edge: CTLA-4 Ligation Delivers a Unique Signal to Resting Human CD4 T Cells That Inhibits Interleukin-2 Secretion but Allows Bcl-XL Induction (1998) (137)
- Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. (2009) (135)
- Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. (2004) (135)
- Telomere Length, Telomerase Activity, and Replicative Potential in HIV Infection: Analysis of CD4+ and CD8+T Cells from HIV-discordant Monozygotic Twins (1997) (135)
- Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. (2008) (133)
- Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia (2018) (132)
- Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019) (2015) (128)
- Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL. (2016) (126)
- Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. (1998) (125)
- CD28-mediated regulation of multiple myeloma cell proliferation and survival. (2005) (124)
- HER‐2 pulsed dendritic cell vaccine can eliminate HER‐2 expression and impact ductal carcinoma in situ (2012) (123)
- Regulation of telomerase RNA template expression in human T lymphocyte development and activation. (1997) (116)
- Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. (2018) (116)
- Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. (2019) (113)
- Dendritic cell-activated CD44hiCD8+ T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity. (2004) (111)
- Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission (2012) (110)
- Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. (2013) (110)
- Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function. (2017) (109)
- Engineered T cells for cancer therapy (2014) (106)
- Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells (2013) (104)
- A Novel Dendritic Cell-based Immunization Approach for the Induction of Durable Th1-polarized Anti-HER-2/neu Responses in Women With Early Breast Cancer (2012) (104)
- Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. (2005) (103)
- T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. (2013) (100)
- TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. (2003) (100)
- Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells (2015) (96)
- Rapid Immune Recovery and Graft-versus-Host Disease–like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells (2009) (93)
- CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction. (1998) (91)
- Regulatory T Cells and Human Myeloid Dendritic Cells Promote Tolerance via Programmed Death Ligand-1 (2010) (91)
- Chimeric Antigen Receptor Therapy for B-cell Malignancies (2011) (90)
- Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. (2013) (89)
- Efficient priming of protein antigen-specific human CD4(+) T cells by monocyte-derived dendritic cells. (2000) (89)
- T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. (2019) (86)
- Intrinsic resistance to T cell infection with HIV type 1 induced by CD28 costimulation. (1997) (83)
- T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer. (1999) (82)
- Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion. (1995) (81)
- Phorbol esters induce differentiation of human CD34+ hemopoietic progenitors to dendritic cells: evidence for protein kinase C-mediated signaling. (1998) (80)
- Ovarian Carcinoma Expresses the NKG2D Ligand Letal and Promotes the Survival and Expansion of CD28− Antitumor T Cells (2004) (80)
- Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist. (2016) (80)
- Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. (2018) (80)
- A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients. (2008) (80)
- Gene expression characteristics of CD28null memory phenotype CD8+ T cells and its implication in T‐cell aging (2005) (79)
- Naı̈ve and Memory CD4 T Cells Differ in Their Susceptibilities to Human Immunodeficiency Virus Type 1 Infection following CD28 Costimulation: Implications for Transmission and Pathogenesis (1998) (77)
- Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas (2015) (76)
- International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19 (2020) (76)
- Tisagenlecleucel Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells (2019) (75)
- The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL). (2017) (73)
- Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL (2013) (73)
- B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study (2016) (70)
- PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial (2022) (67)
- Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma. (2003) (67)
- Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis (2016) (66)
- Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (2016) (64)
- Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes (2011) (61)
- Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM) (2017) (59)
- Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. (2020) (59)
- LETAL, A Tumor-Associated NKG2D Immunoreceptor Ligand, Induces Activation and Expansion of Effector Immune Cells (2003) (59)
- CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. (2019) (58)
- The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. (2020) (56)
- Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. (2006) (54)
- Cell therapy medical tourism: time for action. (2010) (50)
- Chimeric antigen receptor-T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods. (2019) (49)
- CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success (2018) (49)
- miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency. (2016) (48)
- Combination measles, mumps, rubella and varicella vaccine. (1986) (48)
- Activating Signals Dominate Inhibitory Signals in CD137L/IL-15 Activated Natural Killer Cells (2011) (48)
- CAR T-cell product performance in haematological malignancies before and after marketing authorisation. (2020) (47)
- The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28–Costimulated T Cells Prepared for Adoptive Therapy (2015) (47)
- Adoptive immunotherapy: good habits instilled at youth have long-term benefits (2008) (46)
- Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma. (2018) (44)
- Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells (2014) (44)
- Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer. (2015) (44)
- Perspective: Assembly line immunotherapy (2013) (44)
- Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL). (2016) (43)
- Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program. (2009) (42)
- Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. (2011) (42)
- Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (2021) (42)
- Clinical-scale selection of anti-CD3/CD28-activated T cells after transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor. (2002) (40)
- Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells (2004) (40)
- Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. (2017) (39)
- Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL (2015) (39)
- A Novel System for Simultaneous in Vivo Tracking and Biological Assessment of Leukemia Cells and ex Vivo Generated Leukemia-Reactive Cytotoxic T Cells (2004) (38)
- Adoptive Transfer of Autologous T Cells Improves T-cell Repertoire Diversity and Long-term B-cell Function in Pediatric Patients with Neuroblastoma (2012) (38)
- The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion. (1997) (37)
- Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. (2015) (36)
- Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD (2010) (36)
- Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma. (2016) (35)
- Anti-CD3/anti-CD28 bead stimulation overcomes CD3 unresponsiveness in patients with head and neck squamous cell carcinoma. (2000) (34)
- Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL (2013) (34)
- Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL. (2016) (33)
- T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL (2013) (32)
- Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells. (2002) (31)
- Umbilical cord blood xenografts in immunodeficient mice reveal that T cells enhance hematopoietic engraftment beyond overcoming immune barriers by stimulating stem cell differentiation. (2007) (30)
- Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. (2013) (30)
- Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma (2016) (30)
- Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate (2011) (29)
- Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies (2020) (29)
- CCR5-edited CD4 T cells augment HIV-specific immunity to enable post rebound control of HIV replication. (2021) (29)
- Hope, Hype and Help: Ethically Assessing the Growing Market in Stem Cell Therapies (2010) (29)
- Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4(+) T cells to HIV-infected persons. (2004) (29)
- Increases in T cell telomere length in HIV infection after antiretroviral combination therapy for HIV-1 infection implicate distinct population dynamics in CD4+ and CD8+ T cells. (1999) (28)
- Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide (2016) (28)
- Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. (2019) (27)
- Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL (2012) (26)
- Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL. (2016) (25)
- BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. (2021) (25)
- Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation. (2013) (25)
- Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL (2015) (25)
- In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines (2017) (24)
- The role of co-stimulation in regulation of chemokine receptor expression and HIV-1 infection in primary T lymphocytes. (1998) (24)
- Long-Term Functional Persistence, B Cell Aplasia and Anti-Leukemia Efficacy In Refractory B Cell Malignancies Following T Cell Immunotherapy Using CAR-Redirected T Cells Targeting CD19 (2013) (24)
- T cell engineering as therapy for cancer and HIV: our synthetic future (2015) (24)
- Suppressor Function of Umbilical Cord Blood-Derived CD4+CD25+ T-Regulatory Cells Exposed to Graft-versus-Host Disease Drugs (2006) (23)
- Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers (2015) (23)
- T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL (2014) (23)
- Anti-CD3/anti-CD28 monoclonal antibody-coated suture enhances the immune response of patients with head and neck squamous cell carcinoma. (1999) (22)
- Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (2017) (22)
- Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation. (2012) (21)
- Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas (2014) (20)
- Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+ Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy (2016) (20)
- Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. (2020) (20)
- Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. (2020) (19)
- T lymphocyte engineering ex vivo for cancer and infectious disease. (2008) (19)
- CD28 co-receptor signal transduction in T-cell activation. (1997) (19)
- Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (2022) (17)
- Phase I clinical trial of donor T-helper type-2 cells after immunoablative, reduced intensity allogeneic PBSC transplant. (2002) (17)
- ISEV and ISCT statement on EVs from MSCs and other cells: considerations for potential therapeutic agents to suppress COVID-19 (2020) (17)
- CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc). (2012) (17)
- Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma (2018) (17)
- T lymphocyte engineering ex vivo for cancer and infectious disease (2008) (17)
- A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies. (2019) (16)
- Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL). (2017) (16)
- Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR (2016) (16)
- Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia (2016) (16)
- CAR T cell viability release testing and clinical outcomes: is there a lower limit? (2019) (16)
- PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells (2018) (15)
- Adoptive Transfer of Gene-Modified T-Cells Engineered to Express High-Affinity TCRs for Cancer-Testis Antigens (CTAs) NY-ESO-1 or Lage-1, in MM Patients Post Auto-SCT (2012) (14)
- Convergence of gene and cell therapy. (2012) (14)
- Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma. (2015) (14)
- Phase I Trial of Adoptive Cell Transfer with Mixed-Profile Type-I/Type-II Allogeneic T Cells for Metastatic Breast Cancer (2011) (14)
- Anti-CD 19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma (2018) (13)
- Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma. (2016) (12)
- A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD 3 / CD 28 costimulation (2006) (12)
- Phase I study of multi-gene cell therapy in patients with peripheral artery disease (2012) (12)
- TRANCE-and CD 40 Ligand-matured Dendritic Cells Reveal MHC Class I-restricted T Cells Specific for Autologous Tumor in Late-Stage Ovarian Cancer Patients 1 (2003) (12)
- Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma (2019) (12)
- Advances in automated cell washing and concentration. (2021) (11)
- Innovation and opportunity for chimeric antigen receptor targeted T cells. (2013) (11)
- Adoptive Transfer of Umbilical Cord Blood (UCB)-Derived Regulatory T Cells (Tregs) to Recipients of Nonmyeloablative Unrelated Double UCB Transplantation. (2009) (11)
- Impaired Induction of the Apoptosis-Protective Protein Bcl-xL in Activated PBMC from Asymptomatic HIV-Infected Individuals (1997) (10)
- Blocking HIV's attack. (2012) (10)
- Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy (2017) (10)
- IMCT-15PILOT STUDY OF T CELLS REDIRECTED TO EGFRvIII WITH A CHIMERIC ANTIGEN RECEPTOR IN PATIENTS WITH EGFRvIII+ GLIOBLASTOMA (2015) (10)
- High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses (2015) (9)
- Humanized chimeric antigen receptor (CAR)-modified T cells targeting CD19 induce remissions in children and young adults with relapsed/refractory lymphoblastic leukemia/lymphoma (2017) (9)
- The coronavirus pandemic: a pitfall or a fast-track for validating cell therapy products? (2020) (9)
- Recovery of humoral immunity in patients with durable complete responses following chimeric antigen receptor modified t cells directed against CD19 (CTL019). (2016) (9)
- Adoptive T-cell therapy for malignant disorders (2008) (9)
- Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM) (2018) (9)
- Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications (2019) (8)
- Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL (2014) (7)
- CD 28-mediated regulation of multiple myeloma cell proliferation and survival (2007) (7)
- Ex vivo replicative potential of adult human peripheral blood CD4+ T cells. (1997) (7)
- CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia (2018) (7)
- Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma (2019) (6)
- CTL019 Clinical Pharmacology and Biopharmaceutics in Pediatric Patients with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) (2017) (6)
- Accelerating the development of innovative cellular therapy products for the treatment of cancer. (2020) (6)
- Adoptive T-cell therapy for Hodgkin lymphoma (2021) (6)
- CTL019 Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor (CAR) T Cells to Characterize the Impact of Tocilizumab on Expansion and to Identify Correlates of Cytokine Release Syndrome Severity (2017) (6)
- Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment (2016) (5)
- Infection Regulatory T Cells in Hepatitis C Virus + FoxP 3 + Functional Antigen-Specific CD 25 Identification and In Vitro Expansion of (2008) (5)
- Decade-long remissions of leukemia sustained by the persistence of activated CD4+ CAR T-cells (2021) (5)
- Powered and controlled T-cell production (2018) (5)
- T-Rapa Cell Clinical Products Contain a Balance of Minimally Differentiated Th2/Th1 Effector Cells Depleted of Treg Cells (2010) (5)
- Approaches of T Cell Activation and Differentiation for CAR-T Cell Therapies. (2020) (5)
- Predicting T‐cell quality during manufacturing through an artificial intelligence‐based integrative multiomics analytical platform (2021) (5)
- Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products. (2022) (5)
- Engineering T Cells to Survive and Thrive in the Hostile Tumor Microenvironment (2021) (5)
- Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia (2021) (5)
- Signal transduction properties of the T cell activation monoclonal antibody panel: ubiquitous increase in cellular substrate tyrosine phosphorylation in the absence of detectable calcium mobilization. (1996) (5)
- Combination Immunotherapy After ASCT for Multiple Myeloma (MM) Using MAGE-A3/Poly-ICLC Immunizations Followed by Vaccine-Primed and Activated Autologous T-Cells (2012) (5)
- A phase II, dose-optimization trial of autologous T cells genetically engineered to express anti-CD19 chimeric antigen receptor (CART-19) in patients with relapsed or refractory (r/r) CD19+ chronic lymphocytic leukemia (CLL). (2013) (5)
- Effect of chimeric antigen receptor (CAR) T cells on clonal expansion of endogenous non-CAR T cells in patients (pts) with advanced solid cancer. (2017) (5)
- 180 - Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in Non-Hodgkin Lymphoma (NHL) (2017) (5)
- The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. (2021) (4)
- Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia (2016) (4)
- A Randomized Phase II Trial of Idiotype Vaccination and Adoptive Autologous T-Cell Transfer in Multiple Myeloma patients. (2021) (4)
- Successful Translation of Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Cell Processing Technology from Academia to Industry (2015) (4)
- Personalized Cell-Based Medicine: Activated and Expanded T Cells for Adoptive Immunotherapy (2007) (4)
- Abstract PR06: T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce complete responses and long-term persistence without GVHD in children with relapsed, refractory ALL (2014) (4)
- Production of Human CRISPR-Engineered CAR-T Cells. (2021) (4)
- CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL (2021) (4)
- Adoptive transfer of ex vivo costimulated autologous T-cells after autotransplantation for myeloma (MM)accelerates post-transplant T-cell recovery (2004) (3)
- with umbilical cord blood: safety profile and detection kinetics Infusion of ex vivo expanded T regulatory cells in adults transplanted (2011) (3)
- Personalized gene therapy locks out HIV, paving the way to control virus without antiretroviral drugs (2015) (3)
- Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells (2020) (3)
- Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia (2017) (3)
- Adoptive immunotherapy with autologous CD3/CD28-costimulated T cells after fludarabine-based chemotherapy in patients with chronic lymphocytic leukemia. (2011) (3)
- Cancer Killers. (2017) (3)
- Adoptive Transfer of Ex Vivo Costimulated Autologous T-Cells in Conjunction with Pneumococcal Conjugate Vaccine Immunizations Accelerates Post-Transplant T-Cell Recovery after Autotransplantation for Myeloma: Results of a Randomized Study. (2004) (3)
- Enhancing Graft-vs-Tumor (GVT) Activity of Donor Leukocyte Infusions by Ex-Vivo Expansion and Activation with CD3/CD28 Co-Stimulation. (2004) (3)
- Impact of Humoral Immunogenicity (Anti-mCAR19 Antibodies) on CTL019 Cellular Kinetics, Efficacy, and Safety (2017) (3)
- Adoptive Immunotherapy with Autologous CD25-Depleted and CD3/CD28-Costimulated T-Cells (ACTC) Enhances Numeric and Functional Lymphocyte Recovery after Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma. (2005) (3)
- Novel gene and cellular therapy approaches for treating HIV. (2016) (3)
- Adoptive Transfer of Treg-Depleted Donor Th1 and Th2 Cells Safely Accelerates Alloengraftment After Low-Intensity Chemotherapy (2010) (3)
- Response from Carroll et al. (1997) (2)
- Miniatures Mesothelin-Speci fi c Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies (2014) (2)
- Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control (2016) (2)
- Adaptive Immunotherapy with Autologous CD25-Depleted and CD3/CD28-Costimulated T-Cells Enhances Lymphocyte Recovery after Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma. (2006) (2)
- Pilot study of redirected autologous T cells engineered to contain anti-CD19 attached to TCRζ and 4-1BB signaling domains in patients with chemotherapy-resistant or -refractory CD19+ leukemia and lymphoma. (2013) (2)
- Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Syndrome in B-Cell ALL Patients Receiving CART19. (2022) (2)
- 1003. HIV-1-Derived Lentivirus Vector-Based Antisense Gene Therapy: Towards an Alternative Treatment for HIV/AIDS (2004) (2)
- Sustained Functional T Cell Persistence and B Cell Aplasia Following CD19-Targeting Adoptive T Cell Immunotherapy for Relapsed, Refractory CD19+ Malignacy (2012) (2)
- T-Rapa Cell DLI Safely Balances Th1/Th2 Cytokine Activation After Low-Intensity Allogeneic Hematopoietic Cell Transplantation (2011) (2)
- Abstract LB-083: Phase I study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma (2016) (2)
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia (2018) (2)
- Clinical outcomes for anti-CD19 CAR T cell (CTL019) products not meeting commercial release specifications (2020) (2)
- Assays for the Release of Cellular Gene Therapy Products (2007) (2)
- Adoptive transfer of gene-modified T-cells engineered to express high-affinity tcr's for cancer-testis antigens NY-ESO-1 or lage-1, in multiple myeloma (MM) patients post autologous hematopoietic stem cell transplant (ASCT) (2013) (2)
- L-selectin expression defines a subpopulation of In vitro generated AML-reactive T-cells with superior anti-leukemic efficacy for adoptive immunotherapy (2004) (2)
- First Report of the Prophylactic Administration of Ex Vivo Co-Stimulated Donor Lymphocyte Infusion (DLI) from Related and Unrelated Donors after Reduced Intensity Conditioning for High Risk Hematologic Malignancies (2008) (2)
- Progress and challenges in the manufacturing of CAR-T cell therapy (2017) (2)
- Myeloid derived suppressor cells (MDSCS) reduce the manufacturing feasibilty of gene modified T cells. (2019) (2)
- Engineered T-Cells Expressing An HLA-Restricted Affinity-Enhanced TCR In Advanced Multiple Myeloma Patients Post Auto-SCT Engraft and Are Associated With Encouraging Post Auto-SCT Responses (2013) (1)
- T-Rapa6 and T-Rapa12 Cells Differentially Mediate Acute Gvhd after Low-Intensity Allogeneic HCT (2014) (1)
- Rapid T Cell Recovery and Possible Auto-GVHD Following Adoptive Transfer of Ex-Vivo Costimulated Autologous T Cells at Day +2 Post-Transplant. (2007) (1)
- Scholler Antigen Receptor T Cells Decade-Long Safety and Function of Retroviral-Modified Chimeric (2012) (1)
- Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19 (2021) (1)
- Autologous aGVHD Associated with Infusion of T-Cells with Engineered Specificity for NY-ESO-1 and LAGE-1 Following High-Dose Melphalan and ASCT in Patients with Multiple Myeloma (2013) (1)
- Characterization of autologous T cells engineered to express NY-ESO-1 TCR with multiplexed CRISPR/Cas9 editing (NYCE T Cells) (2020) (1)
- Showcasing Clinical Development and Production of Cellular Therapies. (2017) (1)
- Chimeric antigen receptor modified T cells directed against CD19 (CTL019) induce clinical responses in patients with relapsed or refractory CD19+ lymphomas (2015) (1)
- Robust automated cell counter and viability measurement for engineered T cell product release (2018) (1)
- transposon system Sleeping Beauty Stable gene transfer and expression in human primary T cells by the (2012) (1)
- Advances in engineering and synthetic biology toward improved therapeutic immune cells (2021) (1)
- Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals. (2020) (1)
- Anti-CD 3 / Anti-CD 28 Monoclonal Antibody – Coated Suture Enhances the Immune Response of Patients With Head and Neck Squamous Cell Carcinoma (1999) (1)
- Co-stimulated autologous T-cell infusion after autologous stem cell transplantation (SCT) for myeloma accelerates lymphocyte recovery and augments response to pneumoccal vaccine: Results of a randomized trial (2005) (1)
- 1075. Phase I Clinical Trial Demonstrates Safety and Feasibility of Autologous Cellular Therapy with Lentiviral Modified CD4 T Cells Expressing Anti-HIV Antisense in Patients with HAART Resistant HIV-1 Infection (2005) (1)
- Gene expression signatures of response to anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with CLL and ALL. (2017) (1)
- Prophylactic Administration Of Ex VIVO Co-Stimulated Donor Lymphocyte Infusion (DLI) From Related And Unrelated Donors After Reduced Intensity Conditioning For High Risk Hematologic Malignancies (2009) (1)
- Abstract B139: Toxicity testing of EGFRvIII CAR-based immunotherapy of glioblastoma: From bench to bedside (2016) (1)
- The role of CD4+CD25+ T regulatory (Treg) cells in allogeneic bone marrow transplantation (2004) (1)
- B‐cell maturation antigen chimeric antigen receptor T‐cell re‐expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor‐based combination therapy (2021) (1)
- Don’t get lost in translation: How smart design and technology are enabling bench-to-bedside in translational research (2015) (1)
- Abstract 4701: NY-ESO T cells administered post ASCT for MM exhibit extended functionality without exhaustion in a natural pattern of effector and memory programming (2015) (1)
- Impact of CAR T-cell product viability on B-cell lymphoid malignancy outcomes (2019) (1)
- Establishing Safety in the Clinic for the First Lentiviral Vector To Be Tested in Humans. (2004) (1)
- Sleeping Beauty (SB) Transposon Mediated Umbilical Cord Blood (UCB) T Cell Therapy for Refractory Acute Lymphoblastic Leukemia (ALL). (2006) (0)
- The Then, Now, & Future of Engineered T-Cell Therapeutics for Human Application (2022) (0)
- InductionLBcl-X That Inhibits Interleukin-2 Secretion but Allows Unique Signal to Resting Human CD 4 T Cells Cutting Edge : CTLA-4 Ligation Delivers (1997) (0)
- That Inhibits Interleukin-2 Secretion but Allows Unique Signal to Resting Human CD4 T Cells Cutting Edge: CTLA-4 Ligation Delivers a (2013) (0)
- Cell intrinsic PD-1 checkpoint blockade releases the brake on human chimeric antigen receptor (CAR) T cells for solid tumors (2016) (0)
- Adoptive Immunotherapy with Autologous CD3/CD28-Costimulated T-Cells After Fludarabine-Based Chemotherapy in Patients with Chronic Lymphocytic Leukemia (2011) (0)
- Abstract IA10: CARs for leukemia and beyond? (2015) (0)
- Peripheral NK Cell Activation and Expansion by Artificial Antigen Presenting Cells, 2D11 (41.25) (2009) (0)
- Genetically Engineered Antigen Specificity in T Cells for Adoptive Immunotherapy (2011) (0)
- Paving the Road for CAR-Ts: ASTCT 80/20 Task Force consensus on challenges and solutions to improving efficiency of clinical center certification and maintenance of operations for commercially approved immune effector cell therapies. (2023) (0)
- HIV conditionally replicating lentiviral vector expressing long antisense to Antiviral effects of autologous CD 4 T cells genetically modified with a (2013) (0)
- SP-024 CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS FOR RELAPSED,REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (2014) (0)
- Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell (2018) (0)
- Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia (2021) (0)
- Transfer of influenza vaccine–primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial (2010) (0)
- Physicians Abstracts (2014) (0)
- Durable Remissions with Control of Cytokine Release Syndrome (CRS) Using T Cells Expressing CD19 Targeted Chimeric Antigen Receptor (CAR) CTL019 to Treat Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL) (2016) (0)
- Culturing Patient Cells for Cancer Immunotherapy: Challenges and Opportunities (2013) (0)
- Artificial Antigen Presenting Cells (aAPC) Expanded NK-Mediated Enhanced Lysis of Allogeneic Tumor Cells Regardless of HLA Class I/KIR Mismatch and Its Implication of Use in Eradicating Acute Lymphoblastic Leukemia (ALL). (2009) (0)
- CD 28 co-receptor signal transduction in T-cell activation (2009) (0)
- Exploring synthetic immunity: From boutique to global (2017) (0)
- Good Manufacturing Practices Facilities for Cellular Therapy (2018) (0)
- Abstract P6-10-08: Preliminary results of a first in human Phase 1 clinical trial to demonstrate safety and feasibility of chimeric antigen receptor T (CART) cells directed against c-Met in the treatment of breast cancer (2017) (0)
- Multi-Center Phase I Study of Th1/Tc1 Immunotherapy Following Autologous Hematopoietic Progenitor Cell Transplantation in Reccurrent or High Risk Plasma Cell Myeloma (2013) (0)
- T-Lymphocytes: Mature Polyclonal and Antigen-Specific Cell Culture (2002) (0)
- Rapamycin-Induced Autophagy Generates Anti-Apoptotic Th1/Tc1 Cells That Mediate Increased Xenogeneic Gvhd. (2009) (0)
- Costimulated, Tumor-Derived Donor Lymphocyte (TDL) Infusion for B-Cell Tumor Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (2010) (0)
- CLINICAL Cardiovascular toxicity and titin cross-reactivity of af fi nity-enhanced T cells in myeloma and melanoma (2013) (0)
- Adoptive immunotherapy with tumor-derived donor lymphocytes after allogeneic hematopoietic stem cell transplantation (2006) (0)
- Schedule Dependent Effects of Adoptively Transferred Autologous T Cells After AutoSCT for Myeloma: Accelerated Immune Recovery Is Associated with Improved Event-Free Survival. (2009) (0)
- The peril of the promise of speculative cell banking: Statement from the ISCT Committee on the Ethics of Cell and Gene Therapy. (2022) (0)
- Pilot Clinical Trial of Adoptive Immunotherapy with Chimeric, Co-Stimulated Tumor-Infiltrating Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation. (2005) (0)
- Large-scale manufacture of car T cells engineered with augmented proliferative capacity and function via a 3-day process (2021) (0)
- 990. Unexpected Immune Enhancement by Autologous Lentiviral Modified CD4 T Cells: Results from a Phase I Gene Transfer Trial of Lentiviral Vector-Modified T Cells Expressing Antisense Envelope (2005) (0)
- Commercial Autologous Cell Therapy: The Value of Real-Time Patient and Therapy Data (2022) (0)
- Human T Cell Rapamycin Resistance And Th1/Tc1 Polarization Augment Xenogeneic Graft-Versus-Host Disease (2010) (0)
- acute graft-versus-host disease but retain graft-versus-leukemia activity activated CD44hiCD8+ T cells are defective in mediating - Dendritic cell (2013) (0)
- GENE THERAPY Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV (2013) (0)
- Author Correction: Decade-long leukaemia remissions with persistence of CD4+ CAR T cells (2022) (0)
- Abstract 2790: The monocyte lineage is required for production of clinically relevant interleukin-6 (IL-6) during chimeric antigen receptor (CAR) T cell cytotoxicity (2014) (0)
- Keli L . Hippen with Minimal Loss of in Vivo Functional Activity ) regsMassive ex Vivo Expansion of Human Natural Regulatory T Cells ( T (2011) (0)
- A Phase 1 Dose Escalation Study of Infusion of Ex Vivo CD3/CD28 Costimulated Umbilical Cord Blood-Derived T Cells in Adults Undergoing Transplantation for Advanced Hematologic Malignancies (2011) (0)
- Predictive Modeling Demonstrating a Two-Factor Signature As Early As a Week Prior to Harvest For Chimeric Antigen Receptor (CAR) T-Cell Manufacturing Growth (2020) (0)
- B107 Results of a phase 1 using CCR5 Deficiency with Zinc Finger Nuclease-modified Autologous CD4 T Cells (SB-728-T) in HIV-infected Subjects (2013) (0)
- Infection T Cells in Hepatitis C Virus + FoxP3 + Functional Antigen-Specific CD25 Identification and In Vitro Expansion of (2014) (0)
- Ex Vivo Manufacture of Rapamycin-Resistant Human Th1/Tc1 Cells. (2009) (0)
- Abstract 3968: Ovarian cancer chemokine microenvironment is conducive to homing of CD3/CD28 co-stimulated T cells prepared for adoptive transfer therapy. (2013) (0)
- Preemptive T-Rapa Cell DLI after Low Intensity Allogeneic HCT May Allow for Improved Overall Survival in High Risk Lymphoid Malignancies (2016) (0)
- c onvergence of gene and cell therapy (2012) (0)
- Discussion of the requirements, challenges and processing adaptions involved in an academic technology transfer of neo-antigen peptide pulsed dendritic cells (2021) (0)
- Adoptive Transfer of Autologous CD25-Depleted, CD3/CD28-Costimulated T Cells After Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma: Long-Term Follow up (2012) (0)
- Comparable stability of cryopreserved leukapheresis and investigational car t-cell clinical products formulated with in-house or commercial cryomedias (2021) (0)
- Title : Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia (2016) (0)
- Abstract 4575: Correlates of clinical response following autologous stem cell transplant and adoptive immunotherapy with engineered T cells expressing an affinity-enhanced T cell receptor in patients with mutliple myeloma. (2013) (0)
- Prevention of Acute GVHD by Ex Vivo Expanded Umbilical Cord Blood Derived Regulatory T Cells (Treg) (2015) (0)
- Abstract 4574: Use of CD19-targeted Chimeric Antigen Receptor-modified T (CART19) cells in ALL and CLL produce transient cytokine release syndrome (CRS), macrophage activation syndrome (MAS) and durable responses. (2013) (0)
- T Regulatory Expansion and Function CD 28 Costimulation Is Essential for Human June and (2008) (0)
- Chemokine receptors enhance T-cell vaccine cell homing to ovarian cancer (2013) (0)
- Immunotherapy with Autologous Cells (2016) (0)
- Results of a Phase I/II Randomized Immunotherapy Trial Testing Adoptive Transfer of Co-Stimulated Autologous T Cells and Pneumococcal Conjugate Vaccine (PCV) Immunization after Autotransplantation for Myeloma (MM). (2004) (0)
- Use of modified T lymphocytes with chimeric antigen receptors to treat cancer (2011) (0)
- Pre-Emptive T-Rapa Cell DLI for Therapy of High-Risk Lymphoma After Low-Intensity Allogeneic HCT (2012) (0)
- Maintaining excellence in a high volume academic cell therapy production facility through optimization of space utilization, operations, scheduling and staffing (2020) (0)
- Powered and controlled T-cell production (2018) (0)
- 3.18 Ex vivo replicative potential of adults human peripheral blooc CD4+T cells (1996) (0)
- Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells (2018) (0)
- PD-L1 Immuno-Gene Therapy Under Cell Fate Control: Persistence of Cellular Delivery Vehicle and Transgene Expression. (2009) (0)
- Successful Technology Transfer of Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Cell Processing From Academia to Industry Enables Scale-Up to Support Global Clinical Trials (2016) (0)
- ex-vivo via CD3/CD28 co-stimulation A phase I trial of donor lymphocyte infusions expanded and activated (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Bruce L. Levine?
Bruce L. Levine is affiliated with the following schools:
